The daily consumption of one or two doses of ‘Aspirin’ – marketed by Bayer – for at least five years can reduce the risk of colorectal cancer, according to the latest study carried out by the Department of Clinical Epidemiology at Aarhus University Hospital ( Denmark) and who publishes their results in the Annals of Internal Medicine .
For their experiment, the scientists used data from more than 113,000 people they followed for five years . The study group consisted of 10,280 adults and the control group 102,800 participants. The results revealed that those who did not take aspirin did not suffer any alteration in their risk of developing a tumor, however, daily consumption of low doses of aspirin (75-150mg) was associated with a 27% lower risk of developing colorectal cancer .
The benefit of this drug in the prevention of colorectal cancer is contingent on the fact that this type of cancer is especially slow in its progression , so preventive actions usually lead to treatments with a high level of success.
Taking these types of drugs long-term can cause gastrointestinal bleeding, so the researchers insist that no one should start this treatment without a prescription or medical supervision.
“Our findings reveal that low doses of aspirin, already taken regularly by millions of people, reduce the risk of colorectal cancer,” explains study co-author Gurpreet Singh Ranger.
Colorectal cancer is the second leading cause of cancer death, and 9 out of 10 people diagnosed with this type of cancer are under 50 years of age.
